IPO GMP Got All Three Listings Wrong Today: Why Did It Fail?

Three mainboard IPOs listed today, 1 September 2026. All three had closed on 27 August. The grey market had a number ready for each one, and it was wrong on all three – wrong on direction for two, wrong on size for all three, and wrong even on which one would do best.

How wrong was the GMP?

GMP, or grey market premium, is an unofficial price at which IPO applications and allotted shares change hands before listing. It is not an exchange price and nobody guarantees it. Here is what it promised today, and what the market actually gave.

Listing prices from listing-day reports dated 1 September 2026. GMP percentages from IPO Guru's closing readings for issues closed 27 August 2026. BSE opens: Skyways ₹124.50, Symbiotec ₹978.20 (a 0.99% discount), Hy-Tech ₹72 (a 35.85% premium).

Read the last column first. Even Hy-Tech, the one that listed at a strong premium, came in 24.5 percentage points below what the grey market had priced. Somebody expecting ₹88 got ₹75. Still a good day – but not the day the number promised.

The bigger miss is the order. GMP said Skyways (23.19%) would beat Symbiotec (18.72%). The market said the opposite: Symbiotec listed flat, Skyways listed 10% below issue price. So GMP did not just get the size wrong. It got the ranking wrong too.

Skyways is the real surprise. A ₹32 premium on a ₹138 issue meant a 23% pop; instead the stock opened 10% below issue price, a swing of 33 percentage points. And this is no unknown company. Skyways started in 1984 and has been ranked the number one air freight forwarder by World ACD for four years running, 2022 to 2025. The full bid and listing record is on the Skyways Air Services IPO page.

Why GMP goes wrong so often

The grey market is a small, unregulated market run by a handful of dealers in a few trading centres. Volumes are thin, so two or three trades move the quote. Two problems follow from that.

It measures demand, not supply. GMP tells you how badly people wanted the shares before listing. It says nothing about how many of those shares get sold in the first ten minutes of trading. If a big part of the allotment went to people planning to exit on day one, the opening price takes that hit – whatever the premium said last evening.

It stops updating, but the market does not. The last GMP comes the evening before listing. Overnight, sector news, index moves and global cues all land. GMP does not adjust; the exchange price does. That is why every reading on our live IPO GMP tracker carries a timestamp. A GMP without a time on it means very little.

Total subscription also failed. QIB did not.

Many people use subscription numbers as a second check alongside GMP. We have compared IPO GMP against subscription data at length before. Today the headline number failed completely – but one part of it held up.

Final subscription figures for all three issues, closed 27 August 2026, from IPO Guru's subscription data. Listing prices on NSE, 1 September 2026.

Skyways and Symbiotec finished almost level on total subscription – 71.25 times and 71.26 times. One listed flat, the other 10.14% down. The total told you nothing about which was which.

QIB did. Sort by institutional demand: Hy-Tech (255.77x), Symbiotec (172.03x), Skyways (139.69x). Sort by listing gain: Hy-Tech (+41.51%), Symbiotec (0.00%), Skyways (−10.14%). Same order both times.

One warning, and it matters as much as the finding. Three data points falling in the same order can happen by chance roughly one time in six. This is one day's observation, not a tested relationship, and nobody should build a rule out of it. The safer point is narrower: the headline multiple mixes categories that behave very differently, and reading them separately costs nothing.

Retail tells a third story. Hy-Tech drew 170.58 times from retail, against 25.40 times for Skyways and 12.96 times for Symbiotec. That separates the one strong debut from the two weak ones, but it does not order the weak two correctly – Symbiotec had the thinnest retail book and still opened flat. The HNI split is the more interesting one. In Hy-Tech, small HNI bid harder than big HNI (542.10x against 332.38x); in Skyways and Symbiotec it was the other way round. Smaller cheques were excited about exactly one of these three issues, and that is the one that listed well. Watching day-wise subscription status during the issue window lets you see this build up live, instead of reading it afterwards.

The number nobody was looking at

This one sat in the RHP the whole time, and got far less attention than the grey market quote.

Symbiotec's issue was almost entirely an offer for sale. Of ₹1,757 crore raised, only ₹150 crore went to the company, for debt repayment and general corporate purposes. The other ₹1,607 crore went to selling shareholders. Hy-Tech kept ₹60 crore of its ₹135.73 crore issue – ₹30 crore for capital expenditure, ₹16 crore for repaying borrowings, and the rest for general purposes.

In our view, this fresh-issue versus OFS split deserves far more attention than it gets. It answers a simple question: is the money going into the business, or into an existing shareholder's pocket? It is disclosed, it is verifiable, and it does not change overnight. Three companies prove no rule, and OFS-heavy issues have listed strongly many times. But it is a free question to ask before you apply.

What to check instead of GMP

Both Skyways and Symbiotec are real businesses. Symbiotec holds a 36.2% share of global corticosteroid API volumes and 44.2% in steroidal-hormone APIs, from its base in Madhya Pradesh. Today was not a business-quality failure. It was a pricing and expectations failure. All of the below was available before you applied, and none of it sits inside the GMP.

• Profit trend, not revenue size. Symbiotec's FY25 revenue rose 5% to ₹751.6 crore, but profit fell 3.3% to ₹96.8 crore (June 2025 quarter: ₹29.9 crore). Revenue up with profit down is a margin question, and a flat listing is at least consistent with the market noticing.
• Category-wise demand, not the total. Symbiotec's employee quota was subscribed 15.41 times against retail at 12.96 times. Employees bidding harder than the public is a small signal, but a free one.
• Where the fresh money goes. Capacity and capex have a very different future from debt repayment. Symbiotec's management said on listing day that growth should come from complex injectables and fermentation CDMO, with the major capex for both already complete – the company's own statement, not our forecast, but something concrete to check against later results.
• Valuation against listed peers. Post-issue P/E versus the sector median is a ten-minute calculation from the RHP, and the step most people skip. Hy-Tech's market capitalisation reached ₹682.94 crore on debut; whether that is defensible against its earnings is a separate question from whether it listed at a premium.
• Anchor lock-in dates. The 30-day and 90-day expiries are known supply events after listing. They are disclosed. They are not in the GMP.
• Your own holding period. GMP is a one-day number. If you are not selling on day one, it is answering a question you never asked.

Long-term investors usually read an RHP in a fixed order: business model, three-year financials, promoter holding after the issue, use of fresh money, the risk factors in full, and valuation against peers. GMP, if used at all, comes last – as a sentiment reading, not a price target. Subscription data belongs in the same place, just read one layer deeper: watch which category is bidding, and when.